Dr Edward Cornett, DO | |
3690 Orange Pl Ste 150, Beachwood, OH 44122-4476 | |
(216) 839-0933 | |
(216) 839-0934 |
Full Name | Dr Edward Cornett |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 3690 Orange Pl Ste 150, Beachwood, Ohio |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124064274 | NPI | - | NPPES |
1124064274 | Medicaid | OH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 34.004576 (Ohio) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Edward Cornett, DO 21055 Shelburne Rd, Shaker Heights, OH 44122-1945 Ph: (216) 224-1841 | Dr Edward Cornett, DO 3690 Orange Pl Ste 150, Beachwood, OH 44122-4476 Ph: (216) 839-0933 |
News Archive
Researchers at Johns Hopkins have established a high-efficiency cell-cell fusion system, providing a new model to study how fusion works. The scientists showed that fusion between two cells is not equal and mutual as some assumed, but, rather, is initiated and driven by one of the fusion partners. The discovery, they say, could lead to improved treatments for muscular dystrophy, since muscle regeneration relies on cell fusion to make muscle fibers that contain hundreds or even thousands of nuclei.
It has long been acknowledged that breast milk, with its minerals, digestive enzymes and antibodies, keeps babies healthy and boosts their intelligence.
New research shows how top-level sportspeople can struggle to adjust to life after retirement, with their identities continuing to be defined by their former careers.
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.
› Verified 5 days ago
John D Dorsky, MD General Practice Medicare: Medicare Enrolled Practice Location: 3025 Science Park Dr, Beachwood, OH 44122 Phone: 216-455-6330 |